A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Abstract | BACKGROUND: METHODS: RESULTS: A high percentage of enrolled patients are being treated with statins and angiotensin-converting enzyme inhibitors. In the CHARISMA population, a total of 75.6% of the population had an abnormal body mass index: 42.2% were overweight and 33.4% were obese, with particularly high rates in the United States, especially of morbid obesity. Correspondingly, the prevalence of diabetes was 42%. CONCLUSION: The CHARISMA trial will further characterize atherothrombosis and provide insight into the role of dual antiplatelet therapy in improving outcomes in patients with multiple risk factors or established vascular disease. Of note, the rates of obesity and diabetes in patients with atherothrombosis throughout the world are particularly alarming.
|
Authors | Deepak L Bhatt, Keith A Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel Steg, Steven R Steinhubl, Michael A Weber, Joan Booth, Eric J Topol, CHARISMA Investigators |
Journal | American heart journal
(Am Heart J)
Vol. 150
Issue 3
Pg. 401
(Sep 2005)
ISSN: 1097-6744 [Electronic] United States |
PMID | 16169314
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Brain Ischemia
(prevention & control)
- Cardiovascular Diseases
(prevention & control)
- Clopidogrel
- Coronary Disease
(prevention & control)
- Female
- Humans
- Ischemia
(prevention & control)
- Leg
(blood supply)
- Male
- Middle Aged
- Myocardial Infarction
(prevention & control)
- Risk Factors
- Ticlopidine
(analogs & derivatives, therapeutic use)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|